Home | Mini Mixiii Miami

January 8th 2026

The LAB | Wynwood Miami

That’s a Wrap
See you next year
View the full IATI Mini MIXiii Miami 2026 Summary

MIXiii is Coming to Miami!

Mini MIXiii is IATI's satellite event of the MIXiii Health-Tech.IL Conference, serving as an annual gathering for the Life Science and Health Tech industries in Israel.

IATI is thrilled to announce that, for the second time, Mini MIXiii will be held in Miami on January 8th 2026 at The LAB Miami.

This Symposium will showcase leading Israeli Health-Tech startups, offering them the opportunity to connect with key players in the local Miami health tech ecosystem. Attendees can look forward to a focused and dynamic agenda featuring professional networking opportunities, pitch sessions and one-on-one meetings.

Mini MIXiii is an excellent platform for the global Health-Tech industry to exchange knowledge, network, and drive the industry forward into the future.

About the event

8:45am – 9:45am | Registration & Gathering

9:45am-9:48am | Video Greeting Remarks
Isaac Herzog, President of Israel

9:48am – 10:00am | Opening Remarks
Karin Mayer Rubinstein, CEO & President, IATI

Yaacov Michlin, Chairman, MIXiii Health-Tech.IL; CEO, Biolight Life Sciences

Dr. Maurice Ferré, Chair, IATI Mini MIXiii Miami 2026; Chairman and CEO, Insightec

10:00am - 10:10am | Greetings- Guests of Honor
Shevaun L. Harris, Secretary of the Agency for Health Care Administration

10:10am - 10:15am | Greetings- SelectFlorida | Robert Harvey, President, Florida Opportunity Fund

10:15am - 10:25am | Greetings- Local Partners
Scott Srebnick, CEO, Goldman Properties
Ayal Stern, Co-Founder, Miami_Israel Collective

10:25am – 10:35am | Greetings- Israel’s Diplomatic and Economic Representatives in the United States
Nathan Tsror, Head of the Economic Mission to the USA – East Coast
Zuri Siso, Consul General of Israel in Miami

10:35am – 11:05am | Industry Leaders Panel- Building for Scale: Insights from Global Experts
Amazon Web Services; Michael B. Greenwald, Global Head of Executive Relations and Financial Innovation
Teva Pharmaceuticals; Amir Mamo, SVP, Head of U.S. Commercial Operations, Analytics & Data Science
Sullivan & Worcester; Oded Har-Even, Partner and Co-Managing Partner, New York & Tel Aviv Office
Ceros Financial Services; Mark Goldwasser, CEO
Israel Export Institute; Karin Kidron Mor, Director, Digital Health Sector

Moderator: Yaron Shilat, Director of Public Policy Israel, Innovation Policies EMEA at Amazon Web Services

11:05am – 12:55pm | Israeli Companies' CEOs Pitch Sessions
Moderator: Yael Baratz, Partner, Chair of IL Corporate & Licensing Practice Group, Pearl Cohen Zedek Latzer & Baratz

12:55pm – 4:30pm | B2B Meetings + Lunch

IATI Mini MIXiii Miami 2026 - Agenda

Showcasing Israeli Companies Leaders 2026

Yaky Yanay

CEO &President

Pluri

Eran Ophir

President & CEO

Compugen

Kirk Thelander

Chief Commercial Officer

GrayMatters Health

Gili Hart

CEO

SpliSense

Yaacov Michlin

Chairman

OCUVIA

Omer Dror

Co- Founder & CEO

Latica

Ofer Gonen

CEO

MediWound

Yona Geffen

CEO

Cytora

Iftach Dolev

Co- Founder & CEO

Quantalx

Eyal Shamir

CEO

IceCure

Shahar Karny

Co-founder and CEO

PhenoTA

Dori Pelled

CEO

Bsense

Tehila Ben Moshe

CEO & Founder

Biond Biologics

Boaz Almog

CEO

Agile MRI

Startups

Participating Israeli Health-Tech & Life Science Companies

Pluri

Pluri™ is pioneering a biotech revolution with its patented 3D cell-expansion technology, delivering accurate, scalable, and cost-efficient cell production. Its platform powers innovations in regenerative medicine, foodtech, and agtech, and supports partners through CDMO services. By advancing state-of-the-art cell engineering, Pluri helps address global challenges in health, sustainability, food security, and animal welfare.

SpliSense

SpliSense is a clinical-stage biotech developing inhaled RNA-based antisense oligonucleotide (ASO) therapies for severe pulmonary diseases, including cystic fibrosis, COPD, asthma, non-CF bronchiectasis, and IPF. With positive Phase 2 efficacy data in CF and two additional programs entering the clinic by 2026, SpliSense’s platform offers a novel, mutation-independent approach to treating respiratory diseases.

MediWound

MediWound is a global biotechnology company developing and commercializing enzymatic therapies for non-surgical tissue repair. Its FDA-approved biologic, NexoBrid®, removes eschar in burn injuries and is marketed in major regions worldwide. The company’s late-stage candidate, EscharEx®, targets chronic wounds, showing superior clinical outcomes and addressing a significant global market opportunity.

IceCure

IceCure Medical (Nasdaq: ICCM) develops advanced liquid nitrogen-based cryoablation systems for the minimally invasive destruction of tumors by freezing them. Its ProSense System is the first and only FDA-cleared medical device for the local treatment of low-risk breast cancers for women 70 & up when combined with endocrine therapy, giving patients a safe and effective outpatient option to surgery. ProSense is currently sold in the US, Europe, Brazil, and Asia.

Ocuvia

Ocuvia (subsidiary of Biolight) is an ocular-drug delivery company solving one of eye medicine’s biggest challenges: getting therapeutics safely and effectively into the eye. Using two clinically validated platforms—high-dose nano-droplet eye drops and long-acting subconjunctival implants. The droplets (Ocudrip) demonstrated efficacy similar to known injections for AMD and proved safety in humans. The implant (Ocugrid) demonstrated efficacy and safety in PI/IIa in the US.

Biond Biologics

Biond Biologics is a clinical-stage biotech, advancing a innovative pipeline of first-in-class immunotherapies. our key assets: - BND-67 – A first in-class anti CD28 shedding antibody that restores T cell activation driving anti-tumor responses. BND-67 is IND ready, Phase 1 initiation in H1 2026. - BND-22 (SAR444881) – A phase 2A first-in-class ILT2 immune checkpoint inhibitor. - BND-35 – A highly differentiated anti-ILT3 antibody in Phase 1 dose escalation. It blocks all known ILT3 ligands and enhances Fc-effector activity.

Cytora

Cytora is a clinical‑stage biotech company developing a first‑in‑class, off‑the‑shelf cell therapy platform based on human oral mucosa stem cells (hOMSCs), a neural‑crest–derived allogeneic cell population. The platform has already shown strong safety and promising efficacy in two programs: hOMSC200 for hard‑to‑heal diabetic foot ulcers, and hOMSC300 for multiple system atrophy, with early signs of slowed disease progression

Compugen

Compugen Ltd. (Nasdaq/TASE: CGEN) a clinical-stage cancer immunotherapy company pioneering AI/ML-powered drug target discovery via its Unigen™ platform. Its Fc-reduced antibody pipeline includes clinical stage fully owned COM902 (anti-TIGIT), COM701 (anti-PVRIG), and partnered GS-0321 (anti-IL-18BP, licensed to Gilead) as well as Phase 3 rilvegostomig- AstraZeneca’s PD-1/TIGIT bispecific, TIGIT component derived from COM902. Strategic partnerships and differentiated assets position Compugen for long-term growth.

PhenoTA

PhenoTA automates complex manual work in routine lab testing and brings Raman spectroscopy into standard CBCs. Its agent provides real-time insight for faster decisions. The first system is live in Israel, with US pilots planned with leading strategics. PhenoTA raised 6 million dollars and, after a successful FDA presubmission, is preparing its initial 510k study.

Agile MRI

Agile MRI is disrupting musculoskeletal care with a compact, affordable MRI system that delivers rapid, high-value imaging wherever traditional MRI is impractical or unavailable. By giving orthopedic clinics, sports teams, and frontline providers immediate diagnostic insight, Agile MRI enables faster decisions and new revenue opportunities, aiming to make MRI as routine and accessible as X-ray for clinicians nationwide.

GrayMatters Health

GrayMatters Health (GMH) is a mental health technology company developing and marketing an interventional psychiatry suite of treatments and solutions powered by digital fMRI-Informed biomarkers. Prism™ self-neuromodulation empowers patients to develop personal mental strategies to regulate brain activity associated with their condition to treat PTSD (FDA 510(k) cleared) and help them live better with Depression.

Latica

Latica.AI is drastically accelerating pharma go-to-market with actionable clinical data. They partner with specialty physician mega-groups and have unique clinical data from over 30 million patients. Latica's secure data environment is leveraged by AI models that generate market education, patient targeting and clinical protocol development helping pharma and diagnostics products get to market faster. Latica is growing rapidly with a lean, expert team, and are the leading data company in the auto-immunte and inflammatory therapeutic areas

Quantalx

QuantalX Neuroscience™ redefines brain healthcare by empowering clinicians with real-time, accurate insights that eliminate guesswork and accelerate decision-making using Delphi-MD™, the first Functional Neuro-Imaging technology cleared for clinical use. Delphi-MD™ enables earlier, more precise intervention for neurological conditions offering clinicians an effective, non-invasive tool for accessible brain health insights in any care setting.

Bsense

Bsense is a preclinical stage company; developing a novel, orally available, first-in-class, non-opioid approach to treat chronic and neuropathic pain. Lead drug candidate, BSEN760 is a dual modulator targeting of TRPV1 and Kv7.2/3 ion channels, selectively silencing hyperexcitable neurons while preserving normal physiological function. Company is ready to start IND-enabling studies and GMP production of BSEN760 towards initial clinical trials.

Highlights from Mini MIXiii Miami 2025:

MIXiii Health-Tech.IL 2025 Jerusalem- Highlights

Powered by:

Supported by:

CLICK HERE TO BOOK

About_IATI

Israel Advanced Technology Industries Association (IATI)

Fostering the Resilience, Global Competitiveness and the Business Continuity of Israel’s Advanced Technology Industries.

A nonprofit Association of Israel’s advanced tech industry players, IATI is on a mission to foster business certainty and stability for advancing Israel’s high-tech and health-tech industries. This, in turn, furthers national resilience and inclusive economic growth and strengthens Israel’s position as a global innovation leader.

Our members include Israeli tech industry players across all segments – Venture Capital and investment funds, growth and established Israeli companies, R&D centers of Multinational Companies, startups, tech transfer organizations, academic institutions, incubators, innovation centers, hospitals, economic development offices, private investors and service providers.

We connect our members with business opportunities and international stakeholders, building impactful bridges with the global community.

For more information and becoming an IATI Member, please click here

January 8th 2026

The LAB | Wynwood Miami

That’s a Wrap
See you next year
View the full IATI Mini MIXiii Miami 2026 Summary

MIXiii is Coming to Miami!

8:45am – 9:45am | Registration & Gathering

9:45am-9:48am | Video Greeting Remarks
Isaac Herzog, President of Israel

9:48am – 10:00am | Opening Remarks
Karin Mayer Rubinstein, CEO & President, IATI

IATI Mini MIXiii Miami 2026 - Agenda

Showcasing Israeli Companies Leaders 2026

Participating Israeli Health-Tech & Life Science Companies

MediWound

Highlights from Mini MIXiii Miami 2025:

MIXiii Health-Tech.IL 2025 Jerusalem- Highlights

Powered by:

Sponsored by:

Supported by:

Israel Advanced Technology Industries Association (IATI)

Contact Us

Our Address

Call Us

January 8th 2026

The LAB | Wynwood Miami

That’s a Wrap See you next year View the full IATI Mini MIXiii Miami 2026 Summary

MIXiii is Coming to Miami!

8:45am – 9:45am | Registration & Gathering 9:45am-9:48am | Video Greeting Remarks Isaac Herzog, President of Israel 9:48am – 10:00am | Opening Remarks Karin Mayer Rubinstein, CEO & President, IATI

IATI Mini MIXiii Miami 2026 - Agenda

Showcasing Israeli Companies Leaders 2026

Participating Israeli Health-Tech & Life Science Companies

MediWound

Highlights from Mini MIXiii Miami 2025:

MIXiii Health-Tech.IL 2025 Jerusalem- Highlights

Powered by:

Sponsored by:

Supported by:

Israel Advanced Technology Industries Association (IATI)

Contact Us

Our Address

Call Us

That’s a Wrap
See you next year
View the full IATI Mini MIXiii Miami 2026 Summary

8:45am – 9:45am | Registration & Gathering

9:45am-9:48am | Video Greeting Remarks
Isaac Herzog, President of Israel

9:48am – 10:00am | Opening Remarks
Karin Mayer Rubinstein, CEO & President, IATI